Metabolic Disorders
89bio wins EMA priority status for MASH candidate pegozafermin
The European Medicine’s Agency (EMA) has granted priority medicines (PRIME) status to 89bio’s pegozafermin, a drug being evaluated to treat…
EMA CHMP recommends Novo Nordisk’s weekly insulin for diabetes
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Novo Nordisk's Awiqli,…
AstraZeneca snaps up Amolyt for $1.05bn to boost rare disease pipeline
AstraZeneca has signed a definitive agreement to acquire Amolyt Pharma, which specialises in therapies for rare endocrine diseases, in a…
Novo expands Wegovy’s US label to reduce cardiovascular events
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Wegovy (semaglutide) as a treatment to reduce the risk…
Obesity cost US businesses $425.5bn in 2023
A report by GlobalData quantifying the economic impact of obesity and overweight on US businesses and employees has found that…
Novo Nordisk signs $1.46bn deal to develop molecular glue therapies
Novo Nordisk has signed a collaboration and licensing agreement with US-based biotech Neomorph to discover and develop multiple molecular glue…
FDA fast tracks Diamyd’s immunotherapy for managing type 1 diabetes
Swedish biotech Diamyd has won fast track designation for its eponymous type 1 diabetes (T1D) immunotherapy Diamyd (rhGAD65/alum) from the…
BioAge secures $170m for obesity therapeutics development
BioAge Labs has secured $170m in an oversubscribed Series D funding round to progress the development of therapeutics for obesity…
Health Canada approves Chiesi’s MYALEPTA for lipodystrophy
Health Canada has approved Chiesi Group unit Chiesi Global Rare Diseases’ MYALEPTA (metreleptin for injection) to treat individuals with lipodystrophy,…
Q&A: Regulatory reform necessary to improve obesity drug access
Since the massive success of blockbuster diabetes and obesity drugs like Wegovy (semaglutide), and Mounjaro (tirzepatide), there have been several…